Drug Profile
ISIS 388626
Alternative Names: ISIS-SGLT2RxLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antihyperglycaemics; Antisense oligonucleotides
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in Netherlands (SC, Injection)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
- 02 Feb 2012 Isis Pharmaceuticals completes a phase I trial in healthy volunteers (evaluation for Type 2 diabetes mellitus) in the Netherlands (NCT00836225)